Gena Wang
Stock Analyst at Barclays
(0)
# 4503
Out of 5,370 analysts
246
Total ratings
38.21%
Success rate
-11.45%
Average return
Main Sectors:
Top Industries:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
RNA Avidity Biosciences | Maintains: Overweight | 57 59 | 29.84 | 97.72% | 3 | Jun 10, 2025 | |
SLDB Solid Biosciences | Maintains: Overweight | 15 10 | 5.05 | 98.02% | 7 | May 16, 2025 | |
SGMO Sangamo Therapeutics | Maintains: Overweight | 9 5 | n/a | n/a | 4 | May 14, 2025 | |
CLLS Cellectis | Maintains: Overweight | 5 4 | 1.38 | 189.86% | 4 | May 13, 2025 | |
CRSP CRISPR Therapeutics | Maintains: Equal-Weight | 56 42 | 41.66 | 0.82% | 16 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 45 38 | 4.38 | 767.58% | 2 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 56 42 | 51.79 | -18.9% | 15 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 55 53 | 33.75 | 57.04% | 2 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 8 11 | 10.27 | 7.11% | 10 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 31 25 | 16.62 | 50.42% | 9 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 45 40 | 26 | 53.85% | 9 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 40 8 | n/a | n/a | 11 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 26 31 | 5.24 | 491.6% | 6 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 55 26 | 8.96 | 190.18% | 7 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 435 467 | 450.66 | 3.63% | 17 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 5 3 | 2.15 | 39.53% | 9 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 3 4 | 3.77 | 6.1% | 8 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 295 329 | 308.78 | 6.55% | 7 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 110 86 | 56.19 | 53.05% | 13 | Oct 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 226 203 | 20.99 | 867.13% | 7 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 55 50 | 9.14 | 447.05% | 6 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 83 81 | 37.03 | 118.74% | 6 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 45 51 | 35.28 | 44.56% | 9 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 93 94 | 35.8 | 162.57% | 6 | Jan 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 75 71 | n/a | n/a | 6 | Jul 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 145 228 | n/a | n/a | 3 | Mar 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 7 9 | 12.62 | -28.68% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Equal-Weight | 16 25 | 12.89 | 93.95% | 5 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 60 40 | n/a | n/a | 2 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 32 18 | 6.66 | 170.27% | 2 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 72 48 | n/a | n/a | 3 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 30 7 | n/a | n/a | 2 | Mar 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 208 91 | n/a | n/a | 1 | Dec 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 24 8 | 8.18 | -2.2% | 1 | Nov 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 74 79 | n/a | n/a | 1 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | 170 34 | n/a | n/a | 2 | Mar 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 45 34 | n/a | n/a | 4 | May 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 21 9 | 3.44 | 161.63% | 6 | Aug 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | 74 115 | n/a | n/a | 5 | Mar 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | 48 75 | n/a | n/a | 1 | Dec 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | 152 0 | n/a | n/a | 3 | Apr 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | n/a | n/a | n/a | 3 | Jan 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Underweight | 4 | n/a | n/a | 1 | Sep 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 275 | 5.98 | 4498.66% | 1 | Jan 6, 2017 |